Navigation Links
Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
Date:2/10/2012

PRINCETON, N.J., Feb. 10, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced preliminary results today from a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

The Phase 1/2 protocol BDP-ENT-01 was designed as an open label, randomized, dose-finding study at five centers. Sixteen patients with rectal cancer scheduled to undergo concurrent radiation and chemotherapy prior to surgery were enrolled in one of four dose groups, with dosing administered throughout the duration of radiation therapy plus one week. The primary objective of the study was to evaluate the safety and tolerability of escalating doses of SGX201, as well as to assess the preliminary efficacy of SGX201 for prevention of signs and symptoms of acute radiation enteritis. The study was supported in large part by a two-year Small Business Innovation Research (SBIR) grant award from the National Cancer Institute (NCI), which provided Soligenix with approximately $510,000.

The study demonstrated that oral administration of SGX201 was safe and well tolerated across all four dose groups.  There was also evidence of a potential dose response with respect to diarrhea, nausea and vomiting and the assessment of enteritis according to NCI Common Terminology Criteria for Adverse Events for selected gastrointestinal events. In addition, the incidence of diarrhea was lower than that seen in recent published historical control data in this patient population.

"This clinical trial in radiation enteritis with SGX201 provided encouraging exploratory data, which we will be submitting for publication," stated Kevin Horgan, MD, Chief Medical Officer of Soligenix. "Though the numbers are small, the low incidence of diarrhea relative to other similar studies was notable. These findings app
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  The University of Maryland,s A. James Clark ... of the new A. James Clark Hall at the ... cultivate transformative new engineering and biomedical technologies to accelerate ... 10:00 a.m. on November 21 at the site of ... adjacent to the Jeong H. Kim Engineering Building, the ...
(Date:11/21/2014)... Calif. , Nov. 21, 2014 In ... and Performance Scrubs carried out a new product development ... industry,s very first "limited edition" lab coat , ... female professors of surgery in the world. The new ... its unisex predecessors, with a sleek envelope collar, vertical ...
(Date:11/21/2014)... 21, 2014  Heated dialogue in recent months about ... cancer treatments to Gilead,s new hepatitis C drug Harvoni® ... world questioning what it means to put a price ... And while drug pricing is one of the ... both a general business and ethical standpoint – it ...
Breaking Medicine Technology:University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5
... Corporation (Nasdaq: DRRX ) announced today that ... the BIO CEO & Investor Conference on Monday, February ... being held at the Waldorf-Astoria Hotel in New York ... A live audio webcast of the presentation ...
... BD (Becton, Dickinson and Company) (NYSE: BDX ... that it signed a definitive agreement to acquire Accuri ... and manufactures personal flow cytometers for researchers.  The acquisition ... close during the third quarter of fiscal year 2011. ...
Cached Medicine Technology:DURECT to Present at the BIO CEO & Investor Conference 2BD Announces Agreement to Acquire Accuri Cytometers, Inc. 2BD Announces Agreement to Acquire Accuri Cytometers, Inc. 3
(Date:11/21/2014)... TopConsumerReviews.com recently awarded their highest ... in the relief of depression symptoms. ... sadness and depression each year and are unable ... prescription drugs can produce worse side effects than ... and require regular follow-up visits with a doctor. ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 RankingBySEO has ... manage the online reputation of lawyers, and the company ... has announced the service for lawyers since it receives ... online reputation in big numbers. So far, the company ... and law firms in different parts of the world, ...
(Date:11/21/2014)... First Choice Emergency Room ... new facility is located at 225 E. Parkwood Drive, ... are pleased to join the Friendswood community and look ... here,” said Dr. Siddiqi, Facility Medical Director of First ... the opening, First Choice Emergency Room made a donation ...
(Date:11/21/2014)... November 21, 2014 M3 Global Research ... healthcare professional panel, today announced two important leadership changes to ... DasGupta as President of Market Research, Americas and the promotion ... , Ms. DasGupta joined M3 in 2011 and ... recently Head of Sales. Roni has over 17 years ...
(Date:11/21/2014)... Dennis Thompson HealthDay Reporter ... or obese women who get pregnant are much more likely ... an adult, new research suggests. But it looks like ... trend, the researchers added. "Mothers who are overweight teach ... Dr. Michael Mendelson. He is a research fellow at the ...
Breaking Medicine News(10 mins):Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:RankingBySEO Announces Lawyer Reputation Management Service 2Health News:First Choice Emergency Room Opens New Facility in Friendswood, Texas 2Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Kids Born to Overweight Moms May Face Higher Heart Risks as Adults 2
... stillbirths of rodents born to mothers infected with cytomegalovirus// ... loss in newborn children infected in early fetal life. ... ,Estimates place the number of U.S. children born ... is no vaccine or treatment for pregnant women who ...
... evidence to support the link between the common cold ... The study also shows that the link between rhinoviruses ... history of wheezing or asthma. ,Rhinoviruses are ... for at least 50 percent of all common colds. ...
... College of Medicine of Yeshiva University have discovered a ... susceptible to a newly developed molecular targeted therapy. As ... therapy will be able to enroll patients who’ll be ... research was led by Dr. Ari Melnick, assistant professor ...
... about our weight or a bad hair day is ... disorders spend// nearly every waking moment--up to 80 to ... treatment professionals with the Eating Disorders Program at The ... the concern with body shape and size that is ...
... Women’s Health Week will be celebrated May 13-19 this year. ... can take to improve their health. Women often put their ... family members. This week encourages women to be mindful of ... Awareness Day” will be observed on May 15. Sponsored by ...
... According to a report released by International Federation of Red ... by measles//. This disease has so far claimed four lives ... affected by this illness. ,The outbreak began in ... suffering from this infection. There is a steady increase of ...
Cached Medicine News:Health News:CMV Vaccine Prototype Successfully Tested in Guinea Pigs 2Health News:CMV Vaccine Prototype Successfully Tested in Guinea Pigs 3Health News:Children With Asthma Most Affected by Rhinovirus 2Health News:Children With Asthma Most Affected by Rhinovirus 3Health News:Novel Test Identifies Leukemia Patients Likely to Respond to New Therapy 2Health News:Improving Body Image Key to Treating Eating Disorders 2Health News:Improving Body Image Key to Treating Eating Disorders 3Health News:Women’s Health Takes the Spotlight in Ma 2
Bandeau Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test ... Ischemia Modified Albumin (IMA®) by measuring the ... patient serum sample. First identified in the ... albumin comes in contact with ischemic tissue ...
... Binding (ACB®) Test is a clinical chemistry ... by measuring the cobalt binding capacity of ... identified in the early 1990s, IMA is ... with ischemic tissue in the heart. During ...
Medicine Products: